Compare QUIK & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QUIK | CDXS |
|---|---|---|
| Founded | 1988 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Major Chemicals |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.5M | 141.8M |
| IPO Year | 1997 | 2008 |
| Metric | QUIK | CDXS |
|---|---|---|
| Price | $12.50 | $2.51 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | 180.5K | ★ 1.4M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.82 |
| EPS | N/A | ★ N/A |
| Revenue | $20,112,000.00 | ★ $138,590,000.00 |
| Revenue This Year | $75.17 | $7.73 |
| Revenue Next Year | $16.04 | $14.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $4.34 | $0.96 |
| 52 Week High | $12.36 | $3.87 |
| Indicator | QUIK | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 78.14 | 75.03 |
| Support Level | $5.58 | $2.37 |
| Resistance Level | N/A | $2.56 |
| Average True Range (ATR) | 0.63 | 0.17 |
| MACD | 0.21 | 0.05 |
| Stochastic Oscillator | 89.35 | 92.06 |
QuickLogic Corp provides programmable silicon and software platforms to enable its customers to develop custom hardware products in a fast time-to-market and cost-effective way. QuickLogic is a fabless semiconductor company with a product range: embedded FPGA (eFPGA) intellectual property (IP), low power, multi-core semiconductor system-on-chips (SoCs), discrete FPGAs, and AI software. The full range of platforms, software tools, and eFPGA IP enables the practical and efficient adoption of AI, voice, and sensor processing across Aerospace, and Defense, Consumer/Industrial IoT, and Consumer Electronics markets.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.